Epoch Biosciences Will Release First Quarter Results and Host a Confernce Call On May 8

Apr 24, 2001, 01:00 ET from Epoch Biosciences, Inc.

    BOTHELL, Wash., April 24 /PRNewswire Interactive News Release/ -- Epoch
 Biosciences, Inc. (Nasdaq:   EBIO) announced that first quarter 2001 financial
 results will be released on May 8, 2001, prior to market opening.  Dr. William
 G. Gerber, chief executive officer, will host a conference call at
 11:00 am EDT (8:00 am PDT) to discuss the Company's results.
     A live webcast of the conference call may be accessed at
 http://www.vcall.com . To participate, go to vcall.com approximately 15
 minutes before the call is scheduled in order to register and download/install
 the necessary audio software.  A replay of the call will be available for 45
 days.
     To access the call by telephone, domestic callers dial 877/351-9864 and
 international callers dial 706/679-5795.  The passcode is "Epoch."  An audio
 replay will be available for a 24-hour period: domestic callers dial
 800/642-1687 and international callers dial 706/645-9291.  The passcode is
 #806302.
     Epoch Biosciences develops proprietary products with commercial
 applications in the genomics and molecular diagnostics fields.  Epoch's
 technology has numerous applications including the detection of inherited
 diseases and single nucleotide polymorphisms (SNPs) to identify individuals at
 risk for disease or adverse drug reactions.  The Company develops and produces
 chemical reagents that enhance the performance of genetic analysis procedures.
 These reagents are compatible with the majority of DNA analysis systems
 currently employed or under development for research and diagnostic uses.  The
 Company licenses its proprietary chemistry to leading genomics companies for
 incorporation in their systems and distribution to end-users.  Epoch also
 manufactures and sells specialty oligonucleotides and genetic detection
 systems employing its proprietary chemistry.  Information about Epoch is
 available at http://www.epochbio.com .
     Except for the historical information contained herein, the matters set
 forth in this press release, are forward-looking statements within the meaning
 of the "safe harbor" provisions of the Private Securities Litigation Reform
 Act of 1995.  These forward-looking statements are subject to risks and
 uncertainties that may cause actual results to differ materially.  Information
 about potential risk factors that could affect Epoch Bioscience's business and
 financial results is included in Epoch's annual report on Form 10-K for the
 year ended December 31, 2000 and in other reports filed from time to time with
 the Securities and Exchange Commission.
 
     CONTACT:  Bert W. Hogue, Chief Financial Officer of Epoch Biosciences,
 Inc., 425-482-5555.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X04216368
 
 

SOURCE Epoch Biosciences, Inc.
    BOTHELL, Wash., April 24 /PRNewswire Interactive News Release/ -- Epoch
 Biosciences, Inc. (Nasdaq:   EBIO) announced that first quarter 2001 financial
 results will be released on May 8, 2001, prior to market opening.  Dr. William
 G. Gerber, chief executive officer, will host a conference call at
 11:00 am EDT (8:00 am PDT) to discuss the Company's results.
     A live webcast of the conference call may be accessed at
 http://www.vcall.com . To participate, go to vcall.com approximately 15
 minutes before the call is scheduled in order to register and download/install
 the necessary audio software.  A replay of the call will be available for 45
 days.
     To access the call by telephone, domestic callers dial 877/351-9864 and
 international callers dial 706/679-5795.  The passcode is "Epoch."  An audio
 replay will be available for a 24-hour period: domestic callers dial
 800/642-1687 and international callers dial 706/645-9291.  The passcode is
 #806302.
     Epoch Biosciences develops proprietary products with commercial
 applications in the genomics and molecular diagnostics fields.  Epoch's
 technology has numerous applications including the detection of inherited
 diseases and single nucleotide polymorphisms (SNPs) to identify individuals at
 risk for disease or adverse drug reactions.  The Company develops and produces
 chemical reagents that enhance the performance of genetic analysis procedures.
 These reagents are compatible with the majority of DNA analysis systems
 currently employed or under development for research and diagnostic uses.  The
 Company licenses its proprietary chemistry to leading genomics companies for
 incorporation in their systems and distribution to end-users.  Epoch also
 manufactures and sells specialty oligonucleotides and genetic detection
 systems employing its proprietary chemistry.  Information about Epoch is
 available at http://www.epochbio.com .
     Except for the historical information contained herein, the matters set
 forth in this press release, are forward-looking statements within the meaning
 of the "safe harbor" provisions of the Private Securities Litigation Reform
 Act of 1995.  These forward-looking statements are subject to risks and
 uncertainties that may cause actual results to differ materially.  Information
 about potential risk factors that could affect Epoch Bioscience's business and
 financial results is included in Epoch's annual report on Form 10-K for the
 year ended December 31, 2000 and in other reports filed from time to time with
 the Securities and Exchange Commission.
 
     CONTACT:  Bert W. Hogue, Chief Financial Officer of Epoch Biosciences,
 Inc., 425-482-5555.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X04216368
 
 SOURCE  Epoch Biosciences, Inc.